Sudden death

Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

Retrieved on: 
星期二, 五月 7, 2024
LDLR, Patient, Clinical trial, Risk, Safety, Woman, Pharmacokinetics, Blood, ASCVD, Gene, Moyamoya disease, Gene editing, RNA, PCSK9, Life, Ageing, Liver, CAD, Cardiovascular disease, Therapy, Asialoglycoprotein receptor, DSM-IV codes, Apolipoprotein, Sudden death, Pharmaceutical industry

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that the first patient has been dosed with VERVE-102 in the Heart-2 Phase 1b clinical trial. The Heart-2 trial is enrolling adult patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD), two patient populations who require deep reductions of low-density lipoprotein cholesterol (LDL-C) levels in the blood for an extended period of time. Patients living with HeFH have an inherited disorder characterized by elevated blood levels of LDL-C starting early in life. Patients living with premature CAD experience cholesterol-driven blockage of coronary arteries early in life and are at high risk of further complications. A lack of durable control of LDL-C levels in both HeFH and premature CAD patients carries high lifetime risks for cardiovascular events, including heart attack and sudden death.

Key Points: 
  • Patients living with HeFH have an inherited disorder characterized by elevated blood levels of LDL-C starting early in life.
  • Patients living with premature CAD experience cholesterol-driven blockage of coronary arteries early in life and are at high risk of further complications.
  • “Dosing the first patient in the Heart-2 Phase 1b clinical trial for VERVE-102 is an important step in the continued progress of our pipeline,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics.
  • Clinical Trial Applications for the Heart-2 trial have been cleared in Canada and the United Kingdom.

EpiWatch Names Teresa Prego as CEO

Retrieved on: 
星期二, 四月 16, 2024
Sudden death, Social isolation, Seizure, Safety, SUDEP, Johns Hopkins, Death, PWE, Injury, Neurology, Acquisition, Bayer, Clinical trial, Boston Scientific, Pharmaceutical industry

BALTIMORE, April 16, 2024 /PRNewswire/ -- EpiWatch Inc., an AI-enabled medical technology spin-out from Johns Hopkins focused on seizure detection and alerting for people with epilepsy (PWE), announced today that it has named industry veteran Teresa Prego as Chief Executive Officer.

Key Points: 
  • BALTIMORE, April 16, 2024 /PRNewswire/ -- EpiWatch Inc., an AI-enabled medical technology spin-out from Johns Hopkins focused on seizure detection and alerting for people with epilepsy (PWE), announced today that it has named industry veteran Teresa Prego as Chief Executive Officer.
  • Ms. Prego brings a successful track record of commercialization, market entry and operations in multiple early-stage companies.
  • She succeeds founding CEO Dean Papadopoulos, who will remain actively involved with EpiWatch as Chief Strategist and a member of the Board of Directors.
  • "I am excited to join EpiWatch as we focus on commercialization, and the opportunity it creates to drive improved safety and access to care for people with epilepsy," said Ms. Prego.

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
星期一, 四月 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
星期二, 四月 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
星期六, 三月 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
星期四, 三月 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

Retrieved on: 
星期二, 三月 5, 2024
Data Management, Health, Technology, Health Technology, Software, Artificial Intelligence, Cardiology, Cardiovascular disease, Personalized medicine, American Heart Association, Artificial intelligence, MD, Moyamoya disease, Patent, CVD, Entrepreneurship, Splenic infarction, Sudden death, European, Integration, University, Biomarker, CHD, Death, Risk assessment, Patient, Clinical trial, IP, Genomics, Heart, Diagnosis, Medicine, Pharmaceutical industry

This is the second U.S. patent being issued in this patent family.

Key Points: 
  • This is the second U.S. patent being issued in this patent family.
  • Patents in this patent family have also been issued in the European Union, China, India, and Australia.
  • According to the American Heart Association , cardiovascular disease (CVD) claims 2,552 lives daily in the United States, translating to a death every 34 seconds.
  • Heart disease, which includes heart attacks, has been the leading cause of death in the United States for 100 years.

“The Weekly Check-Up Podcast” brings acclaimed healthcare talk radio show to larger audience

Retrieved on: 
星期四, 二月 15, 2024
Cardiovascular disease, Ageing, Acne, Human, Google Podcasts, Blood, Obesity, Health, Skin, Radio, Facial muscles, Letter, Sudden death, Heart failure, Life expectancy, Death, News, Apple Podcasts, Artery, Heart, Immunity, WSB, Spotify, Cancer

“Having produced more than a decade of ‘The Weekly Check-Up’ radio content, it's exciting to introduce a new platform to share the latest healthcare information with as many listeners as possible,” says host Dr. Bruce Feinberg.

Key Points: 
  • “Having produced more than a decade of ‘The Weekly Check-Up’ radio content, it's exciting to introduce a new platform to share the latest healthcare information with as many listeners as possible,” says host Dr. Bruce Feinberg.
  • Since the show began in 2011, Dr. Feinberg has amassed more than 500 hours of content featuring countless thought-provoking questions from listeners.
  • Dr. Feinberg will pair some of the most compelling content from the show’s archives with new, invaluable and practical answers and perspectives.
  • New episodes of “The Weekly Check-Up Podcast” will appear every other week on all major podcast platforms including Spotify, Apple Podcasts, and Google Podcasts.

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

Retrieved on: 
星期四, 一月 25, 2024
Tricuspid valve, Patient, Architecture, Fibrosis, Heart, Hemodynamics, CMR, SAN, Sudden death, Pulmonary fibrosis, LVEF, Research and development, Hypertrophic cardiomyopathy, Disease, Cytokinetics, LVOT, Research, Week, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).
  • At the time of this analysis, 16 patients in FOREST-HCM had completed a CMR at baseline and at Week 48.
  • Baseline characteristics of the CMR cohort were comparable to the overall patient population in FOREST-HCM.
  • We look forward to expanding on these data in the future.”

Huize Achieved a 98.6% Customer Satisfaction Rate for Online Customer Services and Helped over 1 Million Families Resolve Claims in 2023

Retrieved on: 
星期四, 一月 18, 2024
Trust, Policy, Customer service, Intraparenchymal hemorrhage, Sudden death, Insurance, Accident, Poisoning, RMB, Cancer

According to the Customer Service Report, Huize achieved a 98.6% customer satisfaction rate for online customer services and a 99.5% satisfaction rate for teleservices during the year.

Key Points: 
  • According to the Customer Service Report, Huize achieved a 98.6% customer satisfaction rate for online customer services and a 99.5% satisfaction rate for teleservices during the year.
  • The reports revealed that in 2023, Huize served more than one million families with coverage from 11 million insurance policies.
  • In terms of claim settlement services, it showed that Huize provided assistance with 92,000 insurance claims, with a total claim settlement amount of RMB570 million.
  • We are incredibly proud of the high rate of satisfaction reported by customers who used our online services and teleservices in 2023.